A randomized, double-blind, placebo-controlled, three-way crossover, Phase 1 trial to quantitatively assess any effects of IV difelikefalin (CR845) on respiratory drive after bolus infusion in healthy volunteers

Trial Profile

A randomized, double-blind, placebo-controlled, three-way crossover, Phase 1 trial to quantitatively assess any effects of IV difelikefalin (CR845) on respiratory drive after bolus infusion in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Difelikefalin (Primary)
  • Indications Pain; Pruritus
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Mar 2018 According to a Cara Therapeutics media release, the company presented clinical data on the respiratory effects of I.V. CR845 from this trial at ANESTHESIOLOGY 2017, the American Society of Anesthesiologists annual meeting (in Oct 2017).
    • 24 Apr 2017 Data will be presented as part of the Journal Anesthesiology Symposium at the American Society of Anesthesiology (ASA) Annual Meeting, as reported in a Cara Therapeutics media release.
    • 24 Apr 2017 Summary results published in the Cara Therapeutics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top